Stockreport

HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress

HilleVax, Inc.  (HLVX) 
PDF $171.4 million of cash, cash equivalents and marketable securities as of December 31, 2024 The company is exploring the potential for continued development of its norov [Read more]